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Influence of real-world characteristics on
outcomes for patients with methicillin-resistant
Staphylococcal skin and soft tissue infections: a
multi-country medical chart review in Europe
Dilip Nathwani1, Christian Eckmann2, Wendy Lawson3, Caitlyn T Solem4, Shelby Corman4, Jennifer M Stephens4*,
Cynthia Macahilig5, Damien Simoneau6, Richard Chambers7, Jim Z Li8 and Seema Haider9
Abstract
Background: Patient-related (demographic/disease) and treatment-related (drug/clinician/hospital) characteristics
were evaluated as potential predictors of healthcare resource use and opportunities for early switch (ES) from
intravenous (IV)-to-oral methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotic therapy and early hospital
discharge (ED).
Methods: This retrospective observational medical chart study analyzed patients (across 12 European countries)
with microbiologically confirmed MRSA complicated skin and soft tissue infections (cSSTI), ≥3 days of IV anti-MRSA
antibiotics during hospitalization (July 1, 2010-June 30, 2011), and discharged alive by July 31, 2011. Logistic/linear
regression models evaluated characteristics potentially associated with actual resource use (length of IV therapy,
length of hospital stay [LOS], IV-to-oral antibiotic switch), and ES and ED (using literature-based and expert-verified
criteria) outcomes.
Results: 1542 patients (mean ± SD age 60.8 ± 16.5 years; 61.5% males) were assessed with 81.0% hospitalized for
MRSA cSSTI as the primary reason. Several patient demographic, infection, complication, treatment, and hospital
characteristics were predictive of length of IV therapy, LOS, IV-to-oral antibiotic switch, or ES and ED opportunities.
Outcomes and ES and ED opportunities varied across countries. Length of IV therapy and LOS (r = 0.66, p < 0.0001)
and eligibilities for ES and ED (r = 0.44, p < 0.0001) showed relatively strong correlations. IV-to-oral antibiotic switch
patients had significantly shorter length of IV therapy (−5.19 days, p < 0.001) and non-significantly shorter LOS
(−1.86 days, p > 0.05). Certain patient and treatment characteristics were associated with increased odds of ES
(healthcare-associated/ hospital-acquired infection) and ED (patient living arrangements, healthcare-associated/
hospital-acquired infection, initiating MRSA-active treatment 1–2 days post cSSTI index date, existing ED protocol),
while other factors decreased the odds of ES (no documented MRSA culture, ≥4 days from admission to cSSTI index
date, IV-to-oral switch, IV line infection) and ED (dementia, no documented MRSA culture, initiating MRSA-active
treatment ≥3 days post cSSTI index date, existing ES protocol).
Conclusions: Practice patterns and opportunity for further ES and ED were affected by several infection, treatment,
hospital, and geographical characteristics, which should be considered in identifying ES and ED opportunities and
designing interventions for MRSA cSSTI to reduce IV days and LOS while maintaining the quality of care.
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Background
European healthcare systems are under increased economic
pressure owing to greater demand for health services des-
pite stable or declining budgets [1]. Hospitalized patients
with complicated skin and soft tissue infections (cSSTI)
caused by methicillin-resistant Staphylococcus aureus
(MRSA) are a substantial contributor to this clinical and
economic burden [2-4]. The standard treatment option
for patients with MRSA cSSTI is intravenous (IV) anti-
biotic therapy. Patients often remain hospitalized for
the duration of treatment although these infections have
a relatively low risk of complications, readmissions, or
mortality once the patient has been stabilized.
Treatment options are available that allow some of
these patients to complete therapy after discharge from
the hospital with either outpatient parenteral antibiotic
therapy (OPAT) or oral antibiotic therapy, with oral
therapy preferred by patients in many settings [5,6]. Sev-
eral oral antibiotic therapies with activity against MRSA
are available as options for patients with MRSA cSSTI,
including clindamycin, linezolid, rifampicin in combin-
ation with another active agent, doxycycline, and tri-
methoprim/sulfamethoxazole; however, the selection of
therapy must be guided by local susceptibility data, as
MRSA isolate resistance to these oral agents varies [7,8].
Oral antibiotic therapy selection also should be guided
by other properties, such as tolerability, bioavailability,
and efficacy in patients with complicated disease.
In the face of decreasing hospital capacity [9] and in-
creasing economic pressure, exploring approaches to
optimize care is important. One key antibiotic steward-
ship strategy (an approach that supports choice of anti-
biotic therapy, as well as dose, route of administration
and treatment duration) that also has the potential to re-
duce hospital use is to promote IV-to-oral antibiotic
switch therapy, which may facilitate hospital discharge
[10,11]. In an era of scarce resources and tightened
healthcare budgets, understanding which patient and
treatment setting characteristics drive resource use is
important; such resource use includes IV antibiotic days
and length of hospital stay (LOS), as well as characteris-
tics associated with opportunities to optimize care fur-
ther whether met (such as patients who were switched
from IV-to-oral antibiotic therapy) or unmet (including
cases where patients could have been switched from IV-
to-oral antibiotic therapy and/or discharged earlier from
the hospital and received oral antibiotics or OPAT in an
outpatient setting). To address these needs, this study
aimed to explore clinical and demographic characteris-
tics and hospital treatment characteristics associated
with actual healthcare resource use and unmet oppor-
tunities for early switch (ES) from IV-to-oral MRSA-
active antibiotic therapy and early discharge from the
hospital (ED).
Methods
Study population
This is a secondary analysis of a retrospective observa-
tional cohort study which systematically collected data
from the medical charts of patients from 12 European
countries (Austria, the Czech Republic, France, Germany,
Greece, Ireland, Italy, Poland, Portugal, Slovakia, Spain,
and the United Kingdom). The aim of the study was to
describe treatment patterns and healthcare resource use
across Europe and identify opportunities for optimizing
patient switch from IV-to-oral antibiotics (early switch
[ES]) and early discharge (ED) on oral antibiotics or out-
patient parenteral antibiotics [12,13].
Patients meeting the following criteria were identified by
study investigators who were hospital-based infectious dis-
ease specialists, internal medicine specialists with an infec-
tious disease subspecialty, or medical microbiologists: had
microbiologically confirmed MRSA cSSTI (e.g. deep or ex-
tensive cellulitis, infected wound or ulcer, major abscess, or
other soft tissue infections requiring substantial surgical
intervention), received ≥3 days of IV anti-MRSA antibiotics
during their hospitalization (between July 1, 2010 and June
30, 2011, inclusive), and had been discharged alive by July
31, 2011. Anti-MRSA antibiotics included, but were not
limited to clindamycin, daptomycin, fusidic acid, linezolid,
rifampicin, teicoplanin, tigecycline, trimethoprim/sulfa-
methoxazole, and vancomycin. Patients were excluded
from this study if they were treated for the same cSSTI
within 3 months of hospitalization; had suspected or
proven diabetic foot infections, osteomyelitis, infective
endocarditis, meningitis, joint infections, necrotizing soft
tissue infections, gangrene, prosthetic joint infection, or
prosthetic implant/device infection; had significant con-
comitant infection at other sites; were immunosuppressed
(e.g. diagnosed with hematologic malignancy, neutropenia,
or rheumatoid arthritis; were receiving chronic steroids or
cancer chemotherapy); were enrolled in another cSSTI-
related clinical trial; or were pregnant or lactating.
Patients included in the study were randomly sampled
from all patients meeting inclusion/exclusion criteria
from each study investigator’s site. Additionally, we non-
randomly oversampled patients who received IV-to-oral
antibiotic switch therapy to have sufficient sample size
for comparisons between patients receiving IV-only and
IV-to-oral antibiotic switch MRSA-targeted therapy. The
combination of these 2 groups formed the full sample
for this study. After checking the antibiotic treatments
for all patients in the full sample, we confirmed a sub-
sample of patients who received MRSA-active antibiotics
(MRSA treatment sample).
Ethics
The sponsor of the study was blinded to the study inves-
tigators/institutions collecting data, and likewise the
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study investigators/institutions were blinded to the spon-
sor; thus specific names of institutions and ethics boards
are not provided. Ethics approvals were obtained based
on country- and institution-specific requirements for
collection of anonymous, de-identified data from medical
charts. It was the responsibility of the investigator at each
site to have prospective approval of the study protocol,
protocol amendments, and other relevant documents
from the Institutional Review Board(s) (IRB) and/or Inde-
pendent Ethics Committee(s) (IEC), when applicable. In
most EU countries for observational retrospective studies,
only one application was needed; that is, an exemption or
waiver granted to one institution is sufficient or adequate
to present to other institutions that may require it. In-
formed consent was NOT required from the patient under
an Ethics Board review study exempt status. Copies of
IRB/IEC approvals were kept by MDA due to the
double-blind nature of the study. To meet specific country
compliance requirements some registrations and ethics
applications were completed. In Italy, the study was regis-
tered within the central AIFA database. In Germany an
independent review board approval was coordinated and
received by the study sponsor affiliate. In Ireland two hos-
pital ethics board reviews and approvals were received. All
correspondence with the IRB/IEC was retained in the
respective Investigator’s file and at Medical Data Analytics
(MDA). All approval documentation from the IRB/IEC
was retained in the respective Investigator’s file and sub-
mitted to MDA.
Data collection
Medical charts were reviewed using a standardized data
collection form to collect information regarding patient
characteristics and clinical and resource utilization out-
comes. Separate data collection forms were also utilized to
collect site-level characteristics including hospital beds
available and protocols in place for IV antibiotic use and
discharge. All data were retrospectively collected. Key
patient and site characteristics that were collected are
listed in Table 1. In addition, data were collected on pa-
tient treatment patterns including length of IV therapy,
length of stay, and whether the patient was switched
from IV-to-oral antibiotics for treatment of their MRSA
cSSTI and also regarding whether patients had met a
series of criteria which were used to operationalize ES
and ED (described further below).
Real-world healthcare resource use
Length of IV therapy, LOS, and IV-to-oral antibiotic
switch measures were assessed using data abstracted
from patients’ medical charts. This represented actual
(observed) healthcare resource use. Length of IV therapy
was defined as the time between the start of MRSA-
active IV therapy and the last date of inpatient IV
antibiotic use. LOS was measured from the date of hos-
pital admission for patients who were admitted for treat-
ment of MRSA cSSTI, or otherwise from the date of
diagnosis of cSSTI (cSSTI index date) to the date of hos-
pital discharge. IV-to-oral antibiotic switch included any
inpatient who was switched from IV-to-oral antibiotic
therapy before discharge from the hospital.
Opportunities for early switch and early discharge
Opportunities for further reduction in length of IV the-
rapy (ES) or LOS (ED) might exist for some patients. ES
and ED criteria were developed through literature review
[14-21] and expert consensus, and the date that patient
met each of the criteria (if at all) determined retrospect-
ively by the study investigator. ES eligibility required that
the patient meet all of the following criteria prior to IV-to-
oral switch or discontinuation: stable clinical infection;
afebrile (i.e. temperature <38°C for 24 hours); normalized
white blood cell count (i.e. not <4 X 109/L or >12 X 109/
L); no unexplained tachycardia; systolic blood pressure
≥100 mm Hg; and tolerated oral fluids, diet, and medica-
tions with no gastrointestinal absorption problems. ED eli-
gibility required the patient to meet all of the ES criteria
prior to discharge and have no reason to remain hospital-
ized except for infection management.
Statistical analysis
Pearson correlation coefficients were calculated between
outcome variables (LOS, IV days, IV-to-PO switch, ES eligi-
bility, ED eligibility) to determine their interrelationship.
Following this, multivariable regression models were run
for each outcome variable. Before modelling, clinical expert
authors reviewed the list of potential variables to include
in models and identified variables that were clinically im-
portant and as such should always be included within each
multivariable model, as labeled in Table 1. Candidate vari-
ables with a p-value ≤0.1 within bivariate tests (analysis of
variance, chi-squared, correlation) and variables that were
clinically important were tested for inclusion within a series
of statistical models including forward, backward, and
stepwise selection models. Forward selection models forced
the inclusion of all clinically important variables, but back-
wards and stepwise models allowed for removal of these
variables. Models were compared based on their goodness
of fit. In the event that no single model appeared to best fit
the data, clinical authors were consulted regarding which
model was most clinically relevant.
For length of IV therapy and LOS outcomes, ordinary
least-squares linear regression analyses were conducted
using the MRSA treatment sample and the full sample, re-
spectively. For the IV-to-oral antibiotic switch outcome,
logistic regressions used a subgroup of patients in the
MRSA treatment sample who received either IV-only anti-
biotics (reference group) or IV-to-oral antibiotic switch
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therapy. For ES and ED eligibility outcomes, logistic re-
gressions were run using the full sample. Only IV-to-oral
antibiotic switch was considered as both an outcome in
one model and a predictor in subsequent models.
For the purposes of analysis, patients from Ireland
were combined with those from the United Kingdom for
multivariable models, because of Ireland’s small sample
size. The discharge physician’s specialty was used as a
proxy for the treating physician’s specialty, as data on
the latter were not collected. When present, missing
data was treated as a separate category for independent
variables. This most frequently occurred when informa-
tion was not documented within patients’ charts.
Results
Study samples and demographic and clinical
characteristics of the full sample
The full sample included 1542 patients, comprising 1502
patients randomly selected by 342 physicians/sites and an
additional 40 oversampled patients who received IV-to-oral
MRSA-active antibiotic switch therapy. Patients in the full
sample were mean ± standard deviation aged 60.8 ±
16.5 years, with more males (61.5%) than females
(38.5%), and the majority were white (92.9%; Table 2).
Most had MRSA cSSTI as the primary cause of
hospitalization (81.0%). Among the full sample, 1,508 pa-
tients received confirmed MRSA-active therapies, of whom
1,228 received IV-only therapy and 197 received IV-to-oral
antibiotic switch therapy. These 2 groups (a total of 1,425
patients) were used in models of IV-to-oral antibiotic
switch. If patients received both IV and oral medications in
the hospital, but did not switch from IV-to-oral antibiotic
therapy or were discharged on OPAT, they were excluded.
Real-world healthcare resource use
A relatively strong positive correlation was found be-
tween length of IV therapy and LOS (r = 0.66), with a
weaker negative correlation between length of IV ther-
apy and IV-to-oral antibiotic switch (r = −0.18; Table 3).
Outcomes were evaluated by patient baseline characte-
ristics and these outcomes varied across countries. After
adjustment for covariates within multivariable models
(Table 4), patients in Austria, Germany, Greece, Italy,
Poland, and Portugal were significantly less likely to
Table 1 Patient and site characteristics (independent variables) collected from patient charts
Type of data collected Pre-specified as clinically relevant
(always included in models)
Considered in models only if marginally
statistically significant (p < 0.1)
Patient baseline characteristics • Age (later removed), Country, • Patient living arrangements (for IV-only, IV-to-oral,
ES models),
• Patient living arrangements (for LOS, ED models) • Employment status
• Charlson comorbidity index • History of diabetes
• IV drug abuse • History of diabetes with end organ damage
• History of peripheral vascular disease
• History of dementia
• Any MRSA colonization before admission
Infection/treatment
characteristics
• cSSTI type • Days from admission to cSSTI index date
• cSSTI location • Initial antibiotic therapy was MRSA active
• cSSTI source • Time to initiating MRSA-active therapy
• Days to first MRSA culture
• Any surgical procedures for cSSTI
• IV-to-oral antibiotic switch (vs IV-only; except for IV-to-oral
antibiotic switch model)
Complications • Superinfection
• Serious adverse event
• Severe sepsis
• Developed IV line infection
Hospital characteristics • Discharge physician specialty, Type of hospital
• Overall hospital beds,
• Hospital has an ED protocol (IV-to-oral antibiotic
switch or OPAT),
• Hospital has an IV-to-oral antibiotic switch protocol
Abbreviations: cSSTI, complicated skin and soft tissue infection; IV, intravenous; ED, early discharge; ES, early switch; LOS, length of hospital stay; MRSA,
methicillin-resistant Staphylococcus aureus; OPAT, outpatient parenteral antibiotic therapy. Add OPAT?
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switch from IV-to-oral therapy compared with patients
in the United Kingdom or Ireland (all p < 0.05, Table 4).
In addition, the length of IV therapy was longer in
France, Germany, Greece, Italy, Poland, Portugal,
Slovakia, and Spain; LOS was also longer in all of these
countries except Greece and Slovakia (all p < 0.05)
(Additional file 1).
IV drug abuse was associated with significantly longer
length of IV therapy (by 2.78 days) and LOS (by 4.95 days).
Length of IV therapy and LOS also became longer with in-
creasing CCI score, but CCI score did not significantly im-
pact the likelihood of IV-to-oral antibiotic switch
(Table 4). Patients with any MRSA colonization prior to
admission were significantly more likely to be switched
from IV-to-oral antibiotic therapy.
Certain infection characteristics were also associated
with actual treatment patterns (Table 4). Compared with
patients with deep or extensive cellulitis, patients with a
surgical site or posttraumatic wound infection had signifi-
cantly shorter length of IV therapy as well as 2.07 days
shorter LOS (p > 0.05). Compared with patients whose in-
fection was in the torso or abdomen, patients with an
upper extremity infection were significantly more likely to
switch from IV-to-oral therapy, had shorter length of IV
therapy, and shorter LOS. Patients whose infection had
developed ≥4 days after admission had longer LOS after
diagnosis of infection.
In terms of treatment characteristics, IV-to-oral anti-
biotic switch was associated with 5.19 days shorter dur-
ation of IV therapy (p < 0.001) and 1.86 days shorter
LOS (p > 0.05; Table 4). Patients who were discharged
from the hospital and received outpatient parenteral an-
tibiotics had numerically shorter inpatient length of IV
therapy and significantly shorter LOS compared with
those who received IV-only inpatient treatment. Patients
who were not treated with a confirmed MRSA-active
therapy also had a shorter LOS versus patients treated
with IV-only therapy (p < 0.05). Patients whose initial
antibiotic treatment was MRSA-active were significantly
less likely to receive IV-to-oral antibiotic switch therapy
compared with those who received no MRSA-active
therapy and had longer lengths of IV therapy on average.
Interestingly, patients who started MRSA-active treat-
ment 1 or 2 days after their cSSTI index date had
Table 2 Patient demographic and clinical characteristics
in the full sample
Characteristic Overall
(N = 1542)
Mean ± SD age, years 60.8 ± 16.5
Male, n (%) 949 (61.5)
White, n (%) 1432 (92.9)
Mean ± SD CCI score 2.3 ± 2.2
Primary reason for hospitalization is
treatment of MRSA cSSTI, n (%)
1249 (81.0)
Timing of cSSTI index date, n (%)
At hospital admission 1282 (83.1)
1–3 days after admission 49 (3.2)
≥4 days after admission 211 (13.7)
Type of cSSTI, n (%)
Surgical site infection or posttraumatic wound 400 (25.9)
Major abscess 271 (17.6)
Infected ulcer 381 (24.7)
Deep or extensive cellulitis 406 (26.3)
Other (including infected burn) 84 (5.4)
cSSTI location, n (%)
Head/skull/neck 63 (4.1)
Torso/abdomen 325 (21.1)
Upper extremity 232 (15.0)
Lower extremity 922 (59.8)
Sepsis, severe sepsis, or septic shock during cSSTI
episode, n (%)
265 (17.2)
Surgical procedures for treatment of cSSTI, n (%) 597 (38.7)
Mean ± SD number of procedures among patients with any
procedures
0.4 ± 0.6
Patient switched from IV-to-oral inpatient MRSA-active
antibiotic treatment, n (%)
197 (12.8)
Patient received MRSA-targeted therapy at discharge, n (%) 514 (33.3)
Abbreviations: CCI, Charlson comorbidity index; cSSTI, complicated skin and
soft tissue infection; IV, intravenous; MRSA, methicillin-resistant Staphylococcus
aureus; SD, standard deviation.
Table 3 Correlations between key outcomes
IV-to-oral
antibiotic
switch
Length of
IV therapy
LOS ES eligible ED eligible
IV-to-oral antibiotic
switch
r value 1.00 −0.18 −0.03 −0.11 0.05
p value N/A <0.001 0.192 <0.001 0.073
Length of
IV therapy
r value −0.18 1.00 0.66 0.11 0.03
p value <0.001 N/A <0.001 <0.001 0.200
LOS
r value −0.03 0.66 1.00 −0.05 0.02
p value 0.192 <0.001 N/A 0.053 0.482
ES eligible
r value −0.11 0.11 −0.05 1.00 0.44
p value <0.001 <0.001 0.053 N/A <0.001
ED eligible
r value 0.05 0.03 0.02 0.44 1.00
p value 0.073 0.200 0.482 <0.001 N/A
Abbreviations: ED, early discharge; ES, early switch; IV, intravenous; LOS,
length of hospital stay; N/A, not applicable.
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Table 4 Significant covariates within final regression models for actual treatment patterns
Level IV-to-oral antibiotic
switch (n = 1425)
Length of IV
therapy (n = 1508)
LOS (n = 1542)
OR (95% CI) β (SE) β (SE)
Intercept – 5.98 (1.71)*** 24.72 (2.47)***
Patient baseline characteristics
Country (vs Ireland/United Kingdom)
Austria 0.17 (0.04–0.76)* 2.74 (1.49) 2.48 (2.64)
France 1.44 (0.81–2.57) 4.24 (0.93)*** 6.23 (1.66)***
Germany 0.40 (0.21–0.78)** 4.16 (0.97)*** 4.28 (1.74)*
Greece 0.05 (0.01–0.18)*** 2.53 (1.14)* 1.25 (2.03)
Italy 0.23 (0.10–0.55)*** 2.91 (1.04)** 4.69 (1.87)*
Poland 0.19 (0.04–0.90)* 7.65 (1.69)*** 5.97 (2.93)*
Portugal 0.16 (0.06–0.40)*** 4.41 (1.18)*** 4.46 (2.12)*
Slovakia 0.67 (0.23–1.93) 5.29 (1.83)** 3.32 (3.14)
Spain 0.90 (0.49–1.65) 3.10 (1.01)** 5.26 (1.81)**
IV drug abuse 0.72 (0.38–1.34) 2.78 (0.88)** 4.95 (1.72)**
CCI (continuous) 0.96 (0.89–1.04) 0.27 (0.12)* 0.44 (0.21)*
Any MRSA colonization before admission 1.77 (1.13–2.77)*
Not reported/unknown 1.78 (1.19–2.67)**
Infection/treatment characteristics
cSSTI type (vs deep/extensive cellulitis)
Surgical site infection or posttraumatic wound 1.26 (0.77–2.07) −1.39 (0.70)* −2.07 (1.24)
cSSTI location (vs torso/abdomen)
Upper extremity 1.90 (1.09–3.33)* −1.62 (0.80)* −4.97 (1.43)***
Hospital-acquired or healthcare-associated infection unknown/undocumented 0.98 (0.60–1.59) −2.40 (0.68)*** −2.21 (1.20)
Days from admission to cSSTI index date (vs cSSTI at admission)
≥4 days after admission 1.13 (0.64) 5.57 (1.13)***
MRSA-targeted therapy patterns (vs IV-only)
IV-to-oral antibiotic switch – −5.19 (0.74)*** −1.86 (1.32)
Discharged on OPAT – −2.64 (1.59) −6.92 (2.85)*
No MRSA-active antibiotic – – −7.52 (2.98)*
Initial antibiotic therapy was MRSA active (vs was not MRSA active) 0.41 (0.24 - 0.70)** 5.84 (1.01)***
Time to initiating MRSA-active therapy (vs on or before cSSTI index date)
1–2 days post cSSTI index date −1.34 (0.39)*** −2.03 (0.66)**
≥3 days post cSSTI index date 2.20 (0.53)*** 4.18 (0.80)***
Physician specialty (vs GP)a
IM 2.26 (1.43–3.56)*** 1.18 (0.64) 2.86 (1.13)*
Infectious disease 3.01 (1.88–4.82)*** 2.39 (0.73)** 1.28 (1.30)
Surgeon 1.31 (0.70–2.45) 2.73 (0.87)** 5.78 (1.55)***
Any surgical procedures for cSSTI 1.46 (1.00–2.12)* 0.81 (0.54) 1.80 (0.96)
Complications
Severe sepsis 1.93 (0.32)*** 2.32 (0.59)***
Superinfection 3.32 (0.95)***
Developed IV line infection
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significantly shorter length of IV therapy (p < 0.001) and
LOS (p < 0.01) compared with those who initiated
MRSA-active therapy on or before the day their cSSTI
was diagnosed; however, those who initiated therapy
≥3 days after their cSSTI was diagnosed had significantly
longer lengths of IV therapy and LOS (both p < 0.001).
Compared with patients treated by a general practice phys-
ician, patients who were treated by an internal medicine or
infectious disease physician were more likely to be switched
from IV-to-oral therapy. Patients treated by an infectious
disease physician or surgeon had significantly longer length
of IV therapy and patients treated by an internal medicine
physician or surgeon had significantly longer LOS (all p <
0.05). Patients who had (vs those without) any surgical pro-
cedure for their cSSTI were also significantly more likely to
be switched from IV-to-oral therapy, but also had numeric-
ally longer length of IV therapy and LOS.
Length of IV therapy and LOS patterns may have also
been driven by certain infection complications (Table 4).
For example, patients who developed severe sepsis had
significantly longer length of IV therapy and LOS; pa-
tients who developed a superinfection also had signifi-
cantly longer LOS.
When hospital characteristics were considered (Table 4),
patients treated in smaller hospitals (10–249 bed capaci-
ties compared with ≥1000 beds) were significantly more
likely to be switched from IV-to-oral therapy, had
approximately 2 days shorter length of IV therapy and
numerically but not statistically significantly shorter
LOS. Patients treated in a hospital with an IV-to-oral
antibiotic switch protocol also were discharged 2 days
earlier on average (p < 0.05).
Opportunities for early switch and early discharge
A relatively strong positive correlation was found be-
tween eligibilities for ES and ED (r = 0.44). Although
correlations between ES and resource use (i.e. length of
IV therapy and IV-to-oral antibiotic switch) reached stat-
istical significance (p < 0.05), the correlations were gen-
erally negligible (Table 3).
Similar to the results for treatment patterns, variability
was found in the odds of ES and ED eligibility across
countries, with significantly greater odds (compared with
the UK and Ireland) of ES eligibility in Germany, Greece,
and Portugal and greater odds of ED eligibility in the Czech
Republic and Germany, but reduced odds in Slovakia
(Table 5). Patients’ living arrangements significantly im-
pacted ED eligibility, with patients living alone without a
caregiver being significantly more likely to meet ED criteria
compared with those living at home with a caregiver. Pa-
tients with comorbid dementia were also significantly less
likely to be ES and ED eligible (both p < 0.01).
When considering infection characteristics (Table 5),
cSSTI type and location did not appear to have a signifi-
cant impact on ES or ED eligibility. However, patients
with a hospital-acquired or healthcare-associated MRSA
cSSTI were significantly more likely to meet ES and ED
criteria (both p < 0.001). Patients without a documented
MRSA culture were also significantly less likely to meet
ES criteria and ED criteria compared with patients with
first MRSA culture on or before the cSSTI index date.
The amount of time to initiation of MRSA-active ther-
apy impacted ED eligibility, but not ES eligibility
(Table 5). Compared with patients who started MRSA-
active therapy on or before their cSSTI index date, those
who began MRSA-active therapy 1 to 2 days post cSSTI
index date had increased odds of ED eligibility (p < 0.01)
whereas those who started therapy ≥3 days post cSSTI
index date had a decreased likelihood of ED eligibility
(p < 0.01), mirroring the LOS results. The odds of ES
were reduced in patients with ≥4 days from admission to
cSSTI index date compared with patients who had their
cSSTI index date at admission.In relation tocomplications
(Table 5), patients who developed an IV line infection
were significantly less likely to be ES eligible (p < 0.01).
When considering hospital protocols, patients treated
in hospitals that had an IV-to-oral antibiotic switch
protocol were less likely to be ED eligible, while patients
treated in hospitals that had an ED protocol were more
likely to be ED eligible (p < 0.001).
Discussion and conclusions
This analysis highlights the various predictors of IV-
to-oral antibiotic switch, length of IV therapy, LOS, and
opportunities for ES and ED within a selected European
MRSA cSSTI cohort. Both actual practice patterns (i.e.
Table 4 Significant covariates within final regression models for actual treatment patterns (Continued)
Hospital characteristics
Overall hospital beds (vs ≥1000)
10–249 2.37 (1.45–3.88)*** −2.17 (0.77)** −2.17 (1.37)
Hospital had an IV-to-oral antibiotic switch protocol 0.88 (0.61) −2.13 (1.08)*
*p < 0.05; **p < 0.01; ***p < 0.001.
aDischarge physician specialty was used as a proxy for treating physician specialty.
Full versions of the final models, including covariates that were statistically non-significant, are in Additional file 1: Table S1. Abbreviations: CCI, Charlson comorbid-
ity index; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; IV, intravenous; ED, early discharge; ES, early switch; GP, general practitioner; IM,
internal medicine specialist; LOS, length of hospital stay; MRSA, methicillin-resistant Staphylococcus aureus; OPAT, outpatient parenteral antibiotic therapy; OR, odds
ratio; SAE, serious adverse event; SE, standard error.
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IV-to-oral antibiotic switch rates, length of IV therapy,
LOS) and ES and ED eligibility varied significantly across
countries both in bivariate and multivariable analyses.
After adjustment for key clinical and demographic char-
acteristics, actual length of IV therapy and LOS were
lower for patients who received IV-to-oral switch
MRSA-active antibiotic, but the difference was not sta-
tistically significant for LOS. Patients who received IV-
to-oral antibiotic switch therapy appeared to be more
likely to be ED eligible compared with patients treated
with IV-only therapy, although the difference was not
statistically significant.
In reviewing the specific predictors of each outcome, it
should be noted that IV-to-oral antibiotic switch patients
represent those for whom resource use has likely been
optimized in terms of length of IV therapy. Likewise,
some of the patients who were not ED eligible were only
not eligible because they were discharged on the day that
all criteria were met (i.e., discharge was optimized). For
this reason, it is not surprising that a number of vari-
ables were significant predictors for actual practice pat-
terns but they did not significantly predict ES and ED
eligibility. For example, patients with MRSA cSSTI lo-
cated in the upper extremities were more likely to
Table 5 Significant covariates within final regression models for ES and ED eligibility opportunities
Level ES eligibility (n = 1542) ED eligibility (n = 1542)
OR (95% CI) OR (95% CI)
Intercept
Patient baseline characteristics
Country (vs Ireland/United Kingdom)
Czech Republic 0.91 (0.38–2.17) 2.18 (1.01–4.67)*
Germany 2.47 (1.55–3.92)*** 2.05 (1.30–3.24)**
Greece 3.30 (1.99–5.48)*** 1.39 (0.84–2.30)
Portugal 1.75 (1.04–2.95)* 1.67 (0.99–2.83)
Slovakia 0.55 (0.20–1.46) 0.29 (0.10–0.82)*
Patient living arrangements (vs at home with caregiver)
Alone without caregiver 1.33 (1.03–1.72)*
Dementia 0.46 (0.28–0.76)** 0.50 (0.30–0.83)**
Infection/ treatment characteristics
Hospital-acquired or healthcare-associated infection 1.75 (1.30–2.37)*** 1.69 (1.25–2.27)***
Days to first MRSA culture (vs on or before cSSTI index date)
No MRSA culture documented 0.46 (0.30–0.69)*** 0.58 (0.40–0.85)**
Days from admission to cSSTI index date (vs cSSTI at admission)
≥4 days after admission 0.47 (0.32–0.70)* 0.55 (0.38–0.79)
MRSA-targeted therapy patterns (vs IV-only)
IV-to-oral antibiotic switch 0.49 (0.33–0.72)*** 1.40 (1.00–1.96)
Time to initiating MRSA-active therapy (vs on or before cSSTI index date)
1–2 days post cSSTI index date 1.20 (0.92–1.56)**
≥3 days post cSSTI index date 0.71 (0.51–0.99)**
Any surgical procedures for cSSTI 1.13 (0.87–1.45) 1.04 (0.82–1.32)
Complications
Developed IV line infection 0.19 (0.06–0.56)**
Hospital characteristics
Hospital had an IV-to-oral antibiotic switch protocol 0.58 (0.43–0.80)***
Hospital had an ED protocol (IV-to-oral antibiotic switch or OPAT) 1.86 (1.31–2.64)***
*p < 0.05; **p < 0.01; ***p < 0.001.
Full versions of the final models, including covariates that were statistically non-significant, are in Appendix Table 1.
Abbreviations: CCI, Charlson comorbidity index; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; IV, intravenous; ED, early discharge;
ES, early switch; GP, general practitioner; IM, internal medicine specialist; LOS, length of hospital stay; MRSA, methicillin-resistant Staphylococcus aureus; OPAT,
outpatient parenteral antibiotic therapy; SAE, serious adverse event; SE, standard error.
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switch from IV-to-oral antibiotics, had fewer days of IV
therapy, and shorter LOS, but did not have a higher or
lower likelihood of ES/ED eligibility. This highlights an
important difference between length of IV therapy,
LOS, and IV-to-oral antibiotic switch outcomes versus
ES and ED eligibility: practice patterns reflect what ac-
tually happened, while ES and ED eligibility suggest
hypothetical opportunities for improving care. Given
this distinction, these outcomes should plausibly have
different key predictors.
The importance of early treatment for cSSTI was
underscored by patients who received therapy 1 or
2 days after their cSSTI index date having signifi-
cantly lower length of IV therapy and LOS, with in-
creased odds of ED eligibility. In contrast, in patients
whose treatment for cSSTI occurred ≥3 days after
their cSSTI index date, the length of IV therapy and
LOS were significantly longer, with decreased odds of
ED eligibility.
A number of patient- and hospital-level predictors were
found to influence directionality of actual resource
utilization. Treatment in small hospitals (<250 beds)
compared with larger facilities (≥1000 beds), for ex-
ample, was predictive of IV-to-oral antibiotic switch
and fewer IV line days. One potential explanation for
this trend may be that smaller facilities are motivated
by limited resources to minimize IV therapy when pos-
sible. Conversely, patients treated by certain clinical
specialties were associated with significantly longer
length of IV therapy (i.e. infectious disease physicians
or surgeons) and LOS (i.e. internists or surgeons). This
result could be related to treating physicians’ clinical
disciplines, with specialists being more likely to treat
the more severe cSSTI cases compared with non-
specialists. However, information was only available
about the discharge physicians’ specialties, which were
used as a proxy for the treating physicians’ clinical
specialties.
Hospitals with an established IV-to-oral antibiotic
switch protocol had lower odds of ED eligibility, but
were also associated with 2.13 fewer days in LOS, which
could potentially result in cost savings associated with
fewer bed days. Hospitals with ED protocols had nearly
double the odds (OR, 1.86) of patients achieving ED eli-
gibility, which could indicate that these programs are
using different criteria to identify patients who are eli-
gible for ED, or that they are not fully implemented.
One limitation to note was that full information regard-
ing the structure of IV-to-oral antibiotic switch and ED
protocols at the site level were not collected; thus, any
conclusions regarding the impact of these protocols
must be interpreted with care.
Our results can be compared to those observed in other
similar studies, although these studies were smaller and
represent a diverse range of infections and healthcare
systems. Dryden et al. and Gray et al. identified patients
eligible for ES and ED using an evaluation audit tool to
assess patients receiving antibiotic treatment in acute
medical and surgical wards across six centres in the
UK [22,23]. Criteria utilized evaluated the duration of
antibiotic therapy, the patient’s ability to tolerate PO
therapy, the presence of sepsis syndrome, signs and
symptoms indicating infection resolution and the pres-
ence of comorbidities and social factors that could
influence hospital discharge. A total of 34% of patients
requiring antibiotic therapy were eligible for PO
therapy; 21% of patients were eligible for discharge.
Ten patients required OPAT, 55 patients required PO
antibiotic therapy and 24 patients required no therapy.
Factors that appeared to prevent discharge were many
and included waiting for nursing home placement,
requiring social services or rehabilitation, presence of
comorbidities and requiring further medical or surgical
input. These factors are particularly relevant to elderly
patients in acute care. Indeed, another study identified
deconditioning, on-going infection, social issues and
cardiovascular disorders as key factors preventing dis-
charge [24].
Oral antibiotic administration also enables optimization
of inpatient bed use. Between the years 1998 and 2008
hospitals in 15 European countries saw a mean decrease
of 18% in acute care hospital bed capacity per 100, 000
population [9]. During this same time period in 12 Euro-
pean countries there was an average reduction in hos-
pital length of stay (LOS) of 2 days, resulting in a mean
hospital LOS of 6.5 days [9]. A decrease in both acute
care hospital bed capacity and hospital LOS may indicate
a significant pressure on inpatient bed capacity [9]. This re-
duction in inpatient capacity and stay is driven primarily
by changing technology, such as diagnostic and treatment
procedures or techniques that allow patients to be man-
aged in alternative settings, and availability of more effect-
ive treatments [25]. In infectious diseases practice,
progress was made in the development of effective PO
treatments for serious infections, although there is still
substantial growth potential [26].
The results also highlight some of the barriers against
optimizing care, including social situations and health-
care infrastructure. For example, patients with history of
IV drug abuse had longer lengths of IV treatment and
LOS, as did patients with multiple comorbidities. Pa-
tients with dementia, not surprisingly, had lower odds of
ES/ED eligibility. These complex patients represent chal-
lenges in streamlining hospital discharge; however, in
more straightforward patient situations, our study sug-
gests additional opportunities may optimize efficiency of
care. While patient complexity is one barrier, the health-
care infrastructure also plays a role in optimizing care,
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as patients discharged on OPAT had much shorter LOS;
however, not all areas in Europe have well-established
OPAT programs.
This study was conducted as a retrospective medical
chart review and therefore the results were limited by
the completeness of the information that was recorded
in those charts and data that was collected. Of note, pa-
tient preferences, such as the desire to be discharged
sooner, would likely impact actual practice patterns but
unfortunately are not available through chart documen-
tation. While presence of bacteremia secondary to the
presence of the cSSTI may have also been a mediating
factor potentially increasing resource use, this was not
collected and severe sepsis could serve as a surrogate
marker. Likewise we used discharge physician specialty
as a surrogate marker of treating physician specialty in
the absence of this data point.
A large number of patients with documented MRSA
cSSTI were enrolled from 342 sites across 12 European
countries, which provided useful real-world data to
determine potential savings in both length of IV therapy
and hospital bed days. However, patients were not
equally distributed in all of the 12 countries included in
this analysis, with ~70% of them from the following
countries: France, Germany, Italy, Spain, and the United
Kingdom. Nevertheless, this patient distribution may
reflect European MRSA cSSTI epidemiology, since the
countries with fewer patients in these analyses (e.g.
Austria, Slovakia, Poland, Czech Republic) had published
reporting MRSA rates of 7% to 14% compared with at
least 25% in the 5 Western European countries mentioned
above [27].
In conclusion, actual healthcare resource use and ES
and ED eligibility varied significantly across countries
both in bivariate and multivariable analyses. The asso-
ciation of IV-to-oral antibiotic switch therapy with
shorter length of IV therapy days and LOS (though not
significant) indicates that switching patients may be
associated with reduced resource use and hence cost
savings and benefits to patients. Rates of ES and ED
eligibility also indicate that many opportunities are
available to optimize actual practice patterns, particu-
larly through the identification and targeting of inter-
ventions to patient populations with greater eligibility
and longer LOS and IV days. These real world data are
multifaceted and can be challenging in their collection
and interpretation. However, this unique study provides
useful insights into the dynamics of everyday decision
making when managing these patients and we hope
these findings will encourage hospitals across Europe to
examine their systems and processes of care in relation
to ES and ED for this and other therapeutic areas. The
fiscal and quality of care benefits could be potentially
great.
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